Masimo Corp. (MASI) EVP Sells $1,815,000.00 in Stock
Masimo Corp. (NASDAQ:MASI) EVP Yongsam Lee sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $60.50, for a total value of $1,815,000.00. Following the completion of the sale, the executive vice president now directly owns 93,000 shares in the company, valued at approximately $5,626,500. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Masimo Corp. (NASDAQ:MASI) opened at 58.66 on Wednesday. Masimo Corp. has a 52 week low of $33.03 and a 52 week high of $60.81. The firm’s 50-day moving average price is $59.19 and its 200 day moving average price is $51.84. The company has a market cap of $2.89 billion, a P/E ratio of 30.76 and a beta of 0.70.
Masimo Corp. (NASDAQ:MASI) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.16. Masimo Corp. had a return on equity of 29.07% and a net margin of 15.40%. The firm had revenue of $172.64 million for the quarter, compared to analyst estimates of $166.02 million. During the same period in the previous year, the company posted $0.36 earnings per share. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities analysts predict that Masimo Corp. will post $2.02 EPS for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/masimo-corp-masi-evp-sells-1815000-00-in-stock.html
Institutional investors have recently modified their holdings of the stock. Aperio Group LLC raised its position in shares of Masimo Corp. by 27.3% in the first quarter. Aperio Group LLC now owns 15,761 shares of the company’s stock valued at $659,000 after buying an additional 3,379 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Masimo Corp. by 0.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 56,685 shares of the company’s stock valued at $2,372,000 after buying an additional 400 shares in the last quarter. Ngam Advisors L.P. purchased a new position in shares of Masimo Corp. during the first quarter valued at about $461,000. Menta Capital LLC raised its position in shares of Masimo Corp. by 23.5% in the first quarter. Menta Capital LLC now owns 22,100 shares of the company’s stock valued at $925,000 after buying an additional 4,200 shares in the last quarter. Finally, Huntington Asset Advisors Inc. purchased a new position in shares of Masimo Corp. during the first quarter valued at about $513,000. Hedge funds and other institutional investors own 79.88% of the company’s stock.
Several analysts recently issued reports on the company. BTIG Research reissued a “hold” rating on shares of Masimo Corp. in a report on Friday, August 5th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $55.00 price target (up previously from $52.00) on shares of Masimo Corp. in a report on Friday, August 5th. Wedbush reissued an “outperform” rating and issued a $63.00 price target (up previously from $60.00) on shares of Masimo Corp. in a report on Thursday, August 4th. Finally, Zacks Investment Research downgraded Masimo Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $52.60.
About Masimo Corp.
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related companies with MarketBeat.com's FREE daily email newsletter.